pharma · Neurogenic Detrusor Overactivity
Astellas Pharma
Astellas Pharma Europe B. V.
Astellas Pharma Europe is a pharma organization headquartered in EU. Primary therapeutic focus areas include Neurogenic Detrusor Overactivity. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent r
JP HQ
12,378 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- JP
- Employees
- 12,378
- Programs
- 1
- Drugs
- 2
- Patents
- 10
Solifenacin succinate
Phase 3 · small molecule · Neurogenic Detrusor Overactivity
Solifenacin succinate for Neurogenic Detrusor Overactivity is a Phase 3 program (small_molecule) at Astellas Pharma Europe B. V. with 1 ClinicalTrials.gov record(s).
Internal code 905-CL-047
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Astellas Pharma Europe B. V.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Neurogenic Detrusor Overactivity
- Status
- completed
- Trials
- 1